WO2007093746A3 - Utilisation du muraglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques - Google Patents

Utilisation du muraglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques Download PDF

Info

Publication number
WO2007093746A3
WO2007093746A3 PCT/FR2007/050807 FR2007050807W WO2007093746A3 WO 2007093746 A3 WO2007093746 A3 WO 2007093746A3 FR 2007050807 W FR2007050807 W FR 2007050807W WO 2007093746 A3 WO2007093746 A3 WO 2007093746A3
Authority
WO
WIPO (PCT)
Prior art keywords
muraglitazar
preparing
pharmaceutical composition
skin disorders
treating skin
Prior art date
Application number
PCT/FR2007/050807
Other languages
English (en)
Other versions
WO2007093746A2 (fr
Inventor
Jean-Guy Boiteau
Laurence Clary
Michel Rivier
Original Assignee
Galderma Res & Dev
Jean-Guy Boiteau
Laurence Clary
Michel Rivier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev, Jean-Guy Boiteau, Laurence Clary, Michel Rivier filed Critical Galderma Res & Dev
Publication of WO2007093746A2 publication Critical patent/WO2007093746A2/fr
Publication of WO2007093746A3 publication Critical patent/WO2007093746A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à l'utilisation d'au moins un composé choisi parmi l'acide [[(4-méthoxyphénoxy)carbonyl] [4-[2-(5-méthyl-2-phényloxazol-4- yl)éthoxy]benzyl]amino]acétique (Muraglitazar), et ses sels pharmaceutiquement acceptables, pour la préparation d'une composition pharmaceutique destinée à traiter des affections dermatologiques.
PCT/FR2007/050807 2006-02-17 2007-02-15 Utilisation du muraglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques WO2007093746A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0601405A FR2897536A1 (fr) 2006-02-17 2006-02-17 Utilisation du muraglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
FR0601405 2006-02-17

Publications (2)

Publication Number Publication Date
WO2007093746A2 WO2007093746A2 (fr) 2007-08-23
WO2007093746A3 true WO2007093746A3 (fr) 2007-11-22

Family

ID=37101632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/050807 WO2007093746A2 (fr) 2006-02-17 2007-02-15 Utilisation du muraglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques

Country Status (2)

Country Link
FR (1) FR2897536A1 (fr)
WO (1) WO2007093746A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021602A1 (fr) * 1999-09-22 2001-03-29 Bristol-Myers Squibb Company Derives d'oxathiazole et de thiazole utiles comme antidiabetiques et agents contre l'obesite
WO2002012210A1 (fr) * 2000-08-08 2002-02-14 Galderma Research & Development Derives de biphenyle et leur utilisation comme activateurs des recepteurs ppar-gamma
US20040077659A1 (en) * 2002-02-21 2004-04-22 Oliver Jr William Roland Method for treating ppar gamma mediated diseases or conditions
WO2005009437A1 (fr) * 2003-07-21 2005-02-03 Bethesda Pharmaceuticals, Inc. Conception et synthese de ligands optimise pour ppar
WO2005113521A1 (fr) * 2004-05-19 2005-12-01 Bristol-Myers Squibb Company Procede de preparation de carbamates substitues et intermediaires de ceux-ci

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1681054A1 (fr) * 2003-10-29 2006-07-19 Santen Pharmaceutical Co., Ltd. Agent therapeutique destine a des troubles de kerato-conjonctivite

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021602A1 (fr) * 1999-09-22 2001-03-29 Bristol-Myers Squibb Company Derives d'oxathiazole et de thiazole utiles comme antidiabetiques et agents contre l'obesite
WO2002012210A1 (fr) * 2000-08-08 2002-02-14 Galderma Research & Development Derives de biphenyle et leur utilisation comme activateurs des recepteurs ppar-gamma
US20040077659A1 (en) * 2002-02-21 2004-04-22 Oliver Jr William Roland Method for treating ppar gamma mediated diseases or conditions
WO2005009437A1 (fr) * 2003-07-21 2005-02-03 Bethesda Pharmaceuticals, Inc. Conception et synthese de ligands optimise pour ppar
WO2005113521A1 (fr) * 2004-05-19 2005-12-01 Bristol-Myers Squibb Company Procede de preparation de carbamates substitues et intermediaires de ceux-ci

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROSENFIELD R L ET AL: "Mechanisms of androgen induction of sebocyte differentiation", DERMATOLOGY (BASEL), vol. 196, no. 1, 1998, pages 43 - 46, XP009074036, ISSN: 1018-8665 *
ROSENFIELD R L ET AL: "Peroxisome proliferator-activated receptors and skin development.", HORMONE RESEARCH. 2000, vol. 54, no. 5-6, 2000, pages 269 - 274, XP009074035, ISSN: 0301-0163 *

Also Published As

Publication number Publication date
FR2897536A1 (fr) 2007-08-24
WO2007093746A2 (fr) 2007-08-23

Similar Documents

Publication Publication Date Title
WO2007136759A3 (fr) Procédé de traitement et de prévention de troubles oculaires
WO2009055721A3 (fr) Inhibiteur de la protéine d'activation de la 5-lipoxygénase (flap)
WO2009071480A3 (fr) Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
WO2005097135A3 (fr) Utilisation de derives de 9h-purine-2,6-diamine dans le traitement de maladies proliferantes et nouveaux derives de 9h-purine-2,6-diamine
WO2007061661A3 (fr) Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
WO2006121742A3 (fr) Formulations d'inhibiteur de src/abl
IL205974A (en) 2- (5-Bromo-4- (4-Cyclopropylphenaphthalene-1-ram) -4 h-4,2,1- Triazole-3-Ilthio) Acetic acid or salt is acceptable in its pharmacy for use as a drug and a pharmaceutical preparation containing this compound
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
WO2009015812A3 (fr) Prodrogues et leur utilisation
WO2008076392A3 (fr) Composés utilisables en tant qu'inhibiteurs de protéines kinases
WO2007103970A3 (fr) Compositions et procédés de traitement de troubles respiratoires
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
WO2006081431A3 (fr) Composes utiles dans le traitement des maladies auto-immunes et des troubles de demyelinisation
MX346186B (es) Inhibidores de proteina cinasas.
UA96575C2 (en) Process for the preparation of olmesartan medoxomil
WO2010098600A3 (fr) Dérivés d'azole substitués, composition pharmaceutique contenant les dérivés et procédé de traitement de la maladie de parkinson à l'aide de ceux-ci
DE602004018386D1 (de) Verfahren zur herstellung von 4-(2-dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on-hydrochlorid
AU2005313582A8 (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
WO2008006795A3 (fr) Composés d'indole
WO2009109654A8 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1 et cx3cr1
WO2005014572A8 (fr) Derives de pyrimidylpyrrole pouvant etre utilises comme inhibiteurs de kinases
WO2008026048A3 (fr) Compositions pharmaceutiques injectables stables de docétaxel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07731632

Country of ref document: EP

Kind code of ref document: A2